GLP-1 Pill Showdown; $35 Insulin Cap Success; Preterm Births Tied to Plastics

(MedPage Today) -- Novo Nordisk said its semaglutide (Wegovy) pill outperformed recently approved orforglipron (Foundayo) in weight loss and tolerability in an indirect comparison using clinical trial data, and the company launched multi-month...
Source
MedPage Today
Opens original article in a new tab



